Trial Profile
Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 10 Jan 2023 Planned End Date changed from 1 Jan 2023 to 1 Jan 2025.
- 10 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 10 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.